Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study
Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study
复制标题
DOI：
10.1016/j.ophtha.2010.01.056
复制
发表时间：
2010-10-01
期刊：
影响因子：
13.7
通讯作者：
Udaondo-Mirete, Patricia
中科院分区：
文献类型：
--
作者：
Fernando Arevalo, J.;Sanchez, Juan G.;Udaondo-Mirete, Patricia
目的：报告继发于年龄相关性黄斑变性 (AMD) 的黄斑中心凹下脉络膜新生血管 (CNV) 患者初次玻璃体内注射贝伐单抗 (IVB)（阿瓦斯汀；Genentech Inc.，旧金山，加利福尼亚州）（1.25 或 2.5 mg）后的 24 个月解剖和早期治疗糖尿病视网膜病变研究 (ETDRS) 最佳矫正视力 (BCVA) 反应。回顾性、多中心、介入性、比较病例系列。 参与者：我们回顾了来自 8 个国家 9 个中心的 180 名连续患有 AMD 继发黄斑中心凹下 CNV 的患者（207 只眼）的临床记录。 方法：患者接受至少 1 次注射 IVB 1.25 mg（124 只眼 [59.9%]）或 2.5 mg（83 只眼[40.1%]）治疗。患者在基线和 1、3、6、12 和 24 个月就诊时接受了 ETDRS BCVA 测试、检眼镜检查、光学相干断层扫描 (OCT) 和荧光素血管造影 (FA)。主要结果指标：BCVA 和 OCT 的变化。结果：我们患者的平均年龄为 74.3 +/- 7.5 岁。每只眼睛 IVB 注射的平均次数为 5.1 次（范围：1-24 次注射）。在 1.25 mg 组中，24 个月时基线 BCVA 从 20/235（最小分辨率的对数 [logMAR] 1.07）改善至 20/172（logMAR 0.92）（P
Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Design: Retrospective, multicenter, interventional, comparative case series.Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries.Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits.Main Outcome Measures: Changes in BCVA and OCT.Results: The mean age of our patients was 74.3 +/- 7.5 years. The mean number of IVB injections per eye was 5.1 (range, 1- 24 injections). In the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P